TY - JOUR T1 - Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. JF - BJOG Y1 - 2017 A1 - Floridia, M A1 - Masuelli, G A1 - Meloni, A A1 - Cetin, I A1 - Tamburrini, E A1 - Cavaliere, A F A1 - Dalzero, S A1 - Sansone, M A1 - Alberico, S A1 - Guerra, B A1 - Spinillo, A A1 - Chiadò Fiorio Tin, M A1 - Ravizza, M KW - Adult KW - Amniocentesis KW - Analysis of Variance KW - Anti-Retroviral Agents KW - Chi-Square Distribution KW - Chorionic Villi Sampling KW - Female KW - Fetal Death KW - HIV Infections KW - Humans KW - Infectious Disease Transmission, Vertical KW - Odds Ratio KW - Pregnancy KW - Pregnancy Complications, Infectious AB -

OBJECTIVES: To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures.

DESIGN: Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used.

SETTING: University and hospital clinics.

POPULATION: Pregnant women with HIV.

METHODS: Temporal trends were analysed by analysis of variance and by the Chi-square test for trend. Quantitative variables were compared by Student's t-test and categorical data by the Chi-square test, with odds ratios and 95% confidence intervals calculated.

MAIN OUTCOME MEASURES: Rate of invasive testing, intrauterine death, HIV transmission.

RESULTS: Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011-2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005.

CONCLUSIONS: The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment.

TWEETABLE ABSTRACT: No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti-HIV regimens.

VL - 124 IS - 8 U1 - http://www.ncbi.nlm.nih.gov/pubmed/27319948?dopt=Abstract ER -